The rejection of this patent application by The Indian Patent Office was for a combination of existing drugs and techniques.
Following this decision, India can now supply this drug to patients across the world, who are waiting for HIV treatment.
Initiative for Medicines, Access & Knowledge (I-MAK), the not-for-profit organisation, has initiated the legal action over this patent application.
I-MAK Director, Tahir Amin said that Abbott’s track record on pricing this drug unfairly for poorer countries motivated the organisation to take on the case.